secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196467
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q2: $203.2M cash, 9 patients enrolled, Grade 4 ICANS DLT resolved
-------------------------------------------------------------------------------

- R&D expenses $23.4M (Q2 2023: $11.8M); G&A $6.9M (Q2 2023: $4.1M).
- Cash, equivalents and ST investments $203.2M, expected to fund ops into H1 2026.
- Nine patients enrolled across RESET program as of Aug 5; 22 U.S. sites now active.
- LN patient with active refractory disease had Grade 4 ICANS DLT; IDMC recommended study proceed at current dose.
- New Lonza CDMO agreement and expanded Cellares partnership for CABA-201 manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524196467/0001193125-24-196467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524196467/d884570d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer